LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
LivaNova PLC - Ordinary Shares (LIVN)
Last livanova plc - ordinary shares earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
livanova.com
Company Research
Source: Business Wire
Top-line results compared to baseline at six months:Median apnea-hypopnea index reduction of 66.2%Median oxygen desaturation index reduction of 63.3% LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment arm and the sham arm for the LivaNova aura6000™ System. The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA).In the OSPREY study, apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) reductions are analyzed as part of the study’s secondary endpoints. Comparing median values from baseline to six months with therapy (asses
Show less
Read more
Impact Snapshot
Event Time:
LIVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIVN alerts
High impacting LivaNova PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LIVN
News
- LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- How stimulating the body's largest nerve may relieve severe depression [CNN]CNN
- For those with treatment-resistant depression, vagus nerve stimulation may be an answer, studies suggest [CNN]CNN
- RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression [Yahoo! Finance]Yahoo! Finance
- RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant DepressionBusiness Wire
LIVN
Earnings
- 10/30/24 - Beat
LIVN
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LIVN's page on the SEC website